Cancer Research
Newswire |
LEUVEN, Belgium, LUND, Sweden and BASEL, Switzerland, June 18 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (Nordic Exchange: BINV) announce that they have entered into a license agreement with Roche (SWX: ROG) for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal antibody which blocks Placental Growth Factor (PIGF), one of the growth factors responsible for the development of new blood vessels.
Under the terms of the agreement effective from June 17, 2008 (or if a U.S. anti-trust clearance is required, from the date of…
Newswire |
SAN DIEGO, June 17 /PRNewswire/ --
- Strong Government Support Continues to Draw Top Research Institutes, Talent, and Corporate Labs That Are Looking to Place Strategic Bets for the Future
Singapore's investment of more than US$2.1 billion in the biomedical sciences sector has seeded one of the fastest growing bioclusters in the world. R&D spending in the biomedical sciences grew by more than 24% to reach US$760 million in 2006 (from 2005), while the number of research scientists and engineers working in the sector has similarly grown by more than 12% to exceed 2,000 people.
More than 50…
Newswire |
STOCKHOLM, June 17 /PRNewswire/ -- Axelar AB today announced that the company recently has initiated a phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717, an insulin-like growth factor-1 (IGF-1) receptor inhibitor. The phase I/II clinical trial is primarily designed to assess the safety, tolerability, and pharmacokinetics of the drug. As a secondary objective, anti-cancer effects will be documented whenever possible and the study will be conducted in Sweden.
The preclinical research conducted on AXL1717 demonstrated favorable characteristics in potency,…
A new study published today in Annals of Internal Medicine has good news for coffee drinkers: Regular coffee drinking (up to 6 cups per day) is not associated with increased deaths in either men or women. In fact, both caffeinated and decaffeinated coffee consumption is associated with a somewhat smaller rate of death from heart disease.
Women consuming two to three cups of caffeinated coffee per day had a 25 percent lower risk of death from heart disease during the follow-up period (which lasted from 1980 to 2004 and involved 84,214 women) as compared with non-consumers, and an 18 percent…
Newswire |
CHELTENHAM, England, June 14 /PRNewswire/ --
- With Photo
Children from Bishop Stortfor College, Hornsby House School in South London and The Catholic School of St Gregory The Great in Cheltenham had the chance to show some of their artwork to Prince William today (Saturday June 14th) when they attended the annual Chakravarty Cup event at Ham Polo Club in Richmond as special guests of WellChild.
Four pupils aged between 9 and 11 and teachers from the schools have been working to produce art aimed at visually reflecting the work of WellChild - the national children's health charity providing…
Newswire |
BEERSE, Belgium, June 14 /PRNewswire/ --
- 30 Percent Complete Response Rate Compared to 4 Percent With Current Drug Treatment Standard of Care
- Abstract Number: 0473
Janssen-Cilag / Ortho Biotech, the biopharmaceutical division of Janssen- Cilag, today announced unprecedented results from a registration-enabling phase III trial evaluating the VELCADE-based therapy with melphalan and prednisone (VMP) compared with melphalan and prednisone (MP) alone, for previously untreated patients with multiple myeloma (MM) who are not eligible for stem cell transplantation. The study showed VMP achieves…
Newswire |
PLEASANTON, California, June 13 /PRNewswire/ --
- Test offers more reliable detection of Chlamydia trachomatis, the most commonly reported sexually transmitted disease in Europe.
Roche announced today that its new test for detection of Chlamydia trachomatis has received CE Mark certification, allowing it to be sold for clinical use in the European Union. It is designed with a dual target approach to help ensure reliability of test results even when mutations occur in the bacteria's cryptic plasmid DNA. According to Eurosurveillance, a leading independent scientific journal, Chlamydia…
Newswire |
PARIS and AACHEN, Germany, June 13 /PRNewswire/ -- Results from two phase III clinical studies of tapentadol immediate release tablets (IR) suggest a significantly improved gastrointestinal tolerability(1) as well as safety(2) profile compared to oxycodone HCl IR. The data were presented by the German pharmaceutical company Grunenthal at this year's Annual Congress of the European League against Rheumatism (EULAR, June 11-14, Paris, France).
In Europe, one in five adults experiences chronic pain(3) in their life. To reduce pain effectively, especially with chronic pain conditions, the use of…
Newswire |
PARIS, June 13 /PRNewswire/ --
- Rheumatoid Arthritis is the Leading Cause of Work Disability in Europe
New data announced today showed that treating patients with early, active rheumatoid arthritis (RA) with Abbott's HUMIRA(R) (adalimumab) and methotrexate (MTX) resulted in an indirect cost savings of euro 4,845 (or approximately USD$6,086 using exchange rates at the time of the study) per patient per year compared to MTX treatment alone. These cost savings were attributed to improved work performance, ability to gain or regain employment and a reduction in the number of missed workdays. A…
Newswire |
PARIS, June 13 /PRNewswire/ --
Seven-year rheumatoid arthritis (RA) data from open-label extension studies show that treatment with Abbott's HUMIRA(R) (adalimumab) resulted in clinical remission among long-standing RA patients when used in combination with methotrexate (MTX). The percentage of patients achieving clinical remission continued to increase after two or more years of continuous treatment with combination therapy. These data were presented at the European League Against Rheumatism (EULAR) annual meeting in Paris.
The seven-year HUMIRA data are a combined analysis of open-label…